Dr. Reddy's Laboratories Gets Regulatory Nod to Sell Semaglutide Injection in Canada
Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has received a notice of compliance (NOC) from the Canadian regulator, the Pharmaceutical Drugs Directorate (Health Canada), approving its generic Semaglutide Injection, according to a Wednesday filing to the Indian stock exchanges.The issuance of the NOC authorizes the commercialization, sale and distribution of the diabetes control drug Semaglutide Injection in Canada. The market authorization covers the 2 mg/pen (in 1.34 mg/mL) and 4 mg/pen (1.34 mg/mL).The active pharmaceutical ingredient is entirely produced in-house by Dr. Reddy's, with finished product manufacturing currently carried out by the company's manufacturing partner, OneSource Specialty Pharma (NSE:ONESOURCE, BOM:544292).Dr. Reddy's shares were down nearly 1% in recent trade.
